Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Roche’s immunotherapy Tecentriq has shown the first clinical improvement in post-surgery non-small cell lung cancer (NSCLC) although its benefit is limited to certain patients.
Interim results from the phase 3 IMpower010 study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) meeting in June, showed that Tecentriq (atezolizumab) treatment reduced the risk of disease recurrence or death by 34% in people with stage II-IIA NSCLC following surgery and chemotherapy, in patients whose tumours express PD-L1.
Roche added that the median disease-free survival (DFS) was not yet reached for Tecentriq in this population, compared with 35.3 months for best supportive care (BSC).
However, in the larger population (including all randomised stage II-IIA study participants) the benefit was less pronounced – although still significant – with Tecentriq reducing the risk of disease recurrence or death by 21% after a median followup of 32.2 months.
In addition, Tecentriq increased DFS by a median of seven months compared with BSC – 42.3 months versus 35.3 months.
Read more: http://www.pmlive.com/pharma_news/roches_tecentriq_reduces_risk_of_disease_recurrence_or_death_by_34_in_some_nsclc_patients_1370467
Interim results from the phase 3 IMpower010 study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) meeting in June, showed that Tecentriq (atezolizumab) treatment reduced the risk of disease recurrence or death by 34% in people with stage II-IIA NSCLC following surgery and chemotherapy, in patients whose tumours express PD-L1.
Roche added that the median disease-free survival (DFS) was not yet reached for Tecentriq in this population, compared with 35.3 months for best supportive care (BSC).
However, in the larger population (including all randomised stage II-IIA study participants) the benefit was less pronounced – although still significant – with Tecentriq reducing the risk of disease recurrence or death by 21% after a median followup of 32.2 months.
In addition, Tecentriq increased DFS by a median of seven months compared with BSC – 42.3 months versus 35.3 months.
Read more: http://www.pmlive.com/pharma_news/roches_tecentriq_reduces_risk_of_disease_recurrence_or_death_by_34_in_some_nsclc_patients_1370467
